Sol-Gel Technologies Will Host Investor Event in October
The dermatology company will present updates on its SGT-610 drug candidate during an event in New York.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you generally trust corporate announcements regarding new drug development pipelines?
Sol-Gel Technologies will hold a Key Opinion Leader investor event on October 14, 2026, to discuss advancements in the treatment of Gorlin Syndrome. The session will highlight the potential of its topical candidate, SGT-610.
Why it matters
The company aims to address the significant disease burden of Gorlin Syndrome and the limited therapeutic options currently available to patients. The event will provide insights into how topical treatments might offer improved safety compared to existing oral medications.
The SGT-610 candidate features a 2% patidegib gel concentration designed for topical application. The live event is scheduled to begin at 12:00 p.m. ET.
The players
Sol-Gel Technologies
This is a dermatology-focused company headquartered in Ness Ziona, Israel, that specializes in developing topical drugs.
The details
The event in New York will feature presentations from four medical and advocacy experts focused on the clinical applications of SGT-610. Beyond treating Gorlin Syndrome, the company is evaluating the candidate for potential use in high-frequency basal cell carcinoma.
Timeline
September 30, 2026: Sol-Gel Technologies announced the upcoming investor event.
October 14, 2026: The KOL Investor Event will take place in New York at 12:00 p.m. ET.
Roadmap
The development of SGT-610 marks a potential shift in the therapeutic landscape by moving from systemic oral treatments to topical applications for hedgehog pathway inhibition. This transition reflects a broader industry focus on improving safety profiles for patients with chronic dermatological conditions.
Investors and stakeholders can access the event via a live webcast to evaluate the progress of the company's pipeline. Interested parties may contact the company directly to request in-person attendance for the New York session.
The takeaway
Topical delivery systems represent an evolving frontier in dermatology that aims to reduce the side effects often associated with systemic drugs. This event serves as a platform for experts to clarify the clinical viability of such treatments for rare conditions like Gorlin Syndrome.
What happens next
A replay of the webcast and all supporting materials will be made available on the Sol-Gel Investor Relations website following the conclusion of the event on October 14, 2026.
Further reading
Learn more about the latest industry developments in the Biotech section.
Live Poll
Do you generally trust corporate announcements regarding new drug development pipelines?
